Skip to main content

Oncology

Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia

A paper where SGS Exprimo was heavily involved has been recently published in the British Journal of Clinical Pharmacology. Simulo was very useful to evaluate if the PKPD model reproduced adequately nadir values, time to nadir and time to recovery from neutropenia for subjects on chemotherapy.

Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

How modeling and simulation (M&S) supported the development of the immuno-oncology drug pembrolizumab

During his time at Merck (MSD) our consultant Andreas Lindauer participated in the modeling and simulation team that worked on numerous model-informed approaches to support the development of pembrolizumab (KEYTRUDA), a new monoclonal antibody approved for the treatment of melanoma and other cancer types. Check out a series of recently published articles by this M&S team.

How can we help you?